Roche Stock News

The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis AG and Roche Holding AG as soon as Friday, Bloomberg News reported on Wednesday citing people familiar with the situation.

The new cobas® 6800/8800 Systems version 2.0 and software version 2.0.1 enhances throughput, run flexibility, enables sample prioritization and is available as an upgrade to existing systems. Laboratories can now perform a greater variety of tests per run, simplifying laboratory logistics and helping to optimize the use of resources.

Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript

Basel, 11 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has secured CE Mark approval for its mass spectrometry reagent pack for antibiotics drug monitoring. This establishes Roche's in-vitro diagnostics (IVD) menu as the broadest available for any automated mass spectrometry platform, including already 39 of the most frequently tested targets.

Patients as Partners® in Clinical Research Now Part of Questex's Fierce Life Sciences Portfolio; First Conference to Put Patients at the Same Level as R&D Executives in a National Event Takes Place in March in Boston Patients as Partners® in Clinical Research Now Part of Questex's Fierce Life Sciences Portfolio; First Conference to Put Patients at the Same Level as R&D Executives in a National ...

Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, according to the company.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive data from the Phase III lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrine treatment for people with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, early-stage breast cancer. At t...

Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared with standard endocrine therapy, in what it said marked the first big advance in hormonal treatment for the disease in over 20 years.